SCHEMBL13741983

SCHEMBL13741983

CC(C)C(N=[N+]=[N-])c1nc2c(oc3ccccc32)c(=O)n1Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.49
MAPT P10636 6/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPK1 P28482 1/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
LMNA P02545 3/20 0.39
ALDH1A1 P00352 2/20 0.39
TSHR P16473 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PKM P14618 1/20 0.39
USP2 O75604 1/20 0.39
HRH4 Q9H3N8 1/20 0.39
POLB P06746 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13742508 1.00 TP53 (0.49) TP53MAPTHPGDSMN1; SMN2MAPK1
SCHEMBL13981702 0.82 TP53 (0.54) TP53MAPTHPGDSMN1; SMN2MAPK1
SCHEMBL4101970 0.82 TP53 (0.57) TP53MAPTHPGDSMN1; SMN2MAPK1
SCHEMBL4091250 0.82 TP53 (0.54) TP53MAPTHPGDSMN1; SMN2MAPK1
SCHEMBL4101974 0.82 TP53 (0.57) TP53MAPTHPGDSMN1; SMN2MAPK1
SCHEMBL4267618 0.77 TP53 (0.56) TP53MAPTHPGDSMN1; SMN2MAPK1
SCHEMBL13742519 0.76 MAPT (0.41) MAPTHPGDSMN1; SMN2MAPK1MEN1
SCHEMBL13871293 0.74 KIF11 (0.49) MAPTHPGDSMN1; SMN2MEN1KMT2A
SCHEMBL4789503 0.73 TP53 (0.49) TP53MAPTHPGDMEN1KMT2A
SCHEMBL13741951 0.73 TP53 (0.49) TP53MAPTKMT2ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090214529-A9 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2009-08-27 US disclosed
WO-2008147852-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-12-04 WO disclosed
US-20080292626-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090214529-A9 KINESIN INHIBITORS KIF5B, KIF5A, KIF5C TP53 3779/4885MAPT 38/4885HPGD 4076/4885
US-20080292626-A1 KINESIN INHIBITORS KIF5B, KIF5A, KIF5C TP53 3779/4885MAPT 38/4885HPGD 4076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.